中国经济网北京8月4日讯 君实生物(688180.SH)今日股价下跌，截至收盘报37.66元，跌幅1.10%。该股 目前处于破发状态。 君实生物于2020年7月15日在上交所科创板上市，发行数量为8713万股，发行价格为55.50元/股，保荐 机构、主承销商为中国国际金融股份有限公司，联席主承销商为国泰君安证券股份有限公司、海通证券 股份有限公司(2家公司现已合并为国泰海通证券股份有限公司)。 上市首日，君实生物股价最高报220.40元，此后该股一路震荡下滑。该股目前处于破发状态。 君实生物首次公开发行股票募集资金总额为48.36亿元，扣除发行费用后，募集资金净额为44.97亿元， 较原计划多17.97亿元。君实生物于2020年7月8日发布的招股说明书显示，该公司计划募集资金27.00亿 元，分别用于创新药研发项目、君实生物科技产业化临港项目、偿还银行贷款及补充流动资金。 君实生物首次公开发行股票募的发行费用为3.39亿元，其中，保荐及承销费用3.20亿元。 君实生物2022年度向特定对象发行A股股票募集资金情况为，根据中国证监会出具的《关于同意上海君 实生物医药科技股份有限公司向特定对象发行股票注册的批复》 ...

Core Viewpoint - 百奥赛图-B (02315) reported a significant increase in revenue and profitability for the first half of 2025, driven by innovation, market expansion, and optimized management strategies [1] Financial Performance - The company expects revenue for the first half of 2025 to reach between RMB 616 million and RMB 626 million, representing a year-on-year growth of approximately 50.1% to 52.5% [1] - Research and development expenses are projected to be between RMB 206.1 million and RMB 216.1 million, reflecting a year-on-year increase of about 27.5% to 33.6% [1] - The anticipated net profit is between RMB 42.7 million and RMB 52.7 million, indicating a turnaround from previous losses [1] Market Expansion - The company has strengthened its overseas market presence by expanding its sales team and improving its sales system, leading to rapid growth in international business [1] - The release of R&D demand from domestic biopharmaceutical companies has provided development opportunities, particularly in preclinical products and services [1] Technological Edge - 百奥赛图 has established a strong technological barrier with its unique gene editing technology and animal model platform, focusing on over 20 key disease areas and thousands of high-value target models [3] - The company serves nearly 900 pharmaceutical and research institutions globally, completing over 5,300 drug evaluation projects, which supports its preclinical products and services business [3] Diversified Revenue Streams - The antibody licensing and development business is supported by the RenMice platform, which has created a resource library of over one million fully human antibody molecules [4] - By the end of 2024, the company has established around 200 cooperation agreements with various domestic and international pharmaceutical companies, with over 50 licensed projects covering multiple innovative targets [4] - The ongoing expansion of clinical pre-service scale and growth in antibody licensing business is expected to enhance the company's value in the innovative drug industry chain [4]

初步研究结果显示，高剂量组CKBA软膏1.5%BID剂量组的面颈部白癜风评分指数达到F-VASI50和F- VASI25的受试者比例均优于溶媒组(安慰剂组)，其中疾病好转及不同程度复色患者占比为36%(18/50)。 本项临床试验，试验用药品相关不良事件(TEAE)主要为瘙痒、红斑，严重程度均为1-2级，较为轻微， 其中高剂量组CKBA软膏1.5%BID剂量组和溶媒组(安慰剂组)的发生率分别为18%和12%；未发生与试验 用药品相关的严重不良事件(SAE)。表明CKBA软膏具有良好的安全性和耐受性。 本次临床研究初步数据结果显示，CKBA软膏高剂量组面颈部白癜风评分指数优于安慰剂组，具有明显 疗效，同时报告不良事件发生率低、无与试验用药品相关的严重不良事件(SAE)。CKBA作为非免疫抑 制剂，有望为需要长期用药的白癜风患者提供一种安全有效的创新治疗方案。 格隆汇8月4日丨泰恩康(301263.SZ)公布，近日，广东泰恩康医药股份有限公司控股子公司江苏博创园 生物医药科技有限公司(简称"博创园")自主研发的1类创新药CKBA软膏白癜风适应症II期临床试验已于 近日完成数据整理并揭盲。初步结果表明，CKBA软膏 ...

Group 1 - The core point of the article is that Yipinhong (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received acceptance for the clinical trial application of its innovative drug APH03621 from the National Medical Products Administration [1] - APH03621 is a new oral, non-peptide small molecule gonadotropin-releasing hormone receptor antagonist (GnRH-ant) developed by the company, intended for the treatment of endometriosis [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received acceptance for the clinical trial application of its innovative drug APH03621 from the National Medical Products Administration, marking a significant step in the drug's development for the treatment of endometriosis [1] Group 1 - The innovative drug APH03621 is classified as a Class 1 chemical drug and has not been marketed domestically or internationally [1] - The drug is specifically intended for the treatment of endometriosis, a condition that affects many women [1]

泰恩康（301263）(301263.SZ)发布公告，近日，公司控股子公司江苏博创园生物医药科技有限公司(简 称"博创园")自主研发的1类创新药CKBA软膏白癜风适应症II期临床试验已于近日完成数据整理并揭 盲。初步结果表明，CKBA软膏在非节段型白癜风患者中表现出积极的疗效和良好的安全性，试验结果 理想，达到预期目标，支持继续开展III期确证性临床试验，相关研究数据也将在近期提交CDE进行突破 性疗法申请和注册临床的沟通交流。 此次CKBA软膏白癜风适应症获得II期临床试验研究初步结果且达到预期目标，进一步验证了CKBA作 为首个靶向T细胞脂肪酸代谢通路的FIC(First-in-Class)创新小分子药物在自身免疫性疾病领域的巨大开 发潜力。公司将加快推进白癜风适应症III期临床试验和玫瑰痤疮适应症II/III期临床试验，并持续深入开 展CKBA在靶点和作用机制方面的基础研究，进一步拓展其在自身免疫性疾病领域的相关适应症。 ...

此次CKBA软膏白癜风适应症获得II期临床试验研究初步结果且达到预期目标，进一步验证了CKBA作 为首个靶向T细胞脂肪酸代谢通路的FIC(First-in-Class)创新小分子药物在自身免疫性疾病领域的巨大开 发潜力。公司将加快推进白癜风适应症III期临床试验和玫瑰痤疮适应症II/III期临床试验，并持续深入开 展CKBA在靶点和作用机制方面的基础研究，进一步拓展其在自身免疫性疾病领域的相关适应症。 智通财经APP讯，泰恩康(301263.SZ)发布公告，近日，公司控股子公司江苏博创园生物医药科技有限公 司(简称"博创园")自主研发的1类创新药CKBA软膏白癜风适应症II期临床试验已于近日完成数据整理并 揭盲。初步结果表明，CKBA软膏在非节段型白癜风患者中表现出积极的疗效和良好的安全性，试验结 果理想，达到预期目标，支持继续开展III期确证性临床试验，相关研究数据也将在近期提交CDE进行突 破性疗法申请和注册临床的沟通交流。 ...

初步研究结果显示，高剂量组CKBA软膏1.5%BID剂量组的面颈部白癜风评分指数达到F-VASI50和F- VASI25的受试者比例均优于溶媒组(安慰剂组)，其中疾病好转及不同程度复色患者占比为36%(18/50)。 本项临床试验，试验用药品相关不良事件(TEAE)主要为瘙痒、红斑，严重程度均为1-2级，较为轻微， 其中高剂量组CKBA软膏1.5%BID剂量组和溶媒组(安慰剂组)的发生率分别为18%和12%；未发生与试验 用药品相关的严重不良事件(SAE)。表明CKBA软膏具有良好的安全性和耐受性。 本次临床研究初步数据结果显示，CKBA软膏高剂量组面颈部白癜风评分指数优于安慰剂组，具有明显 疗效，同时报告不良事件发生率低、无与试验用药品相关的严重不良事件(SAE)。CKBA作为非免疫抑 制剂，有望为需要长期用药的白癜风患者提供一种安全有效的创新治疗方案。 格隆汇8月4日丨泰恩康(301263.SZ)公布，近日，广东泰恩康医药股份有限公司控股子公司江苏博创园 生物医药科技有限公司(简称"博创园")自主研发的1类创新药CKBA软膏白癜风适应症II期临床试验已于 近日完成数据整理并揭盲。初步结果表明，CKBA软膏 ...

每经AI快讯，8月4日，泰恩康（301263）(301263.SZ)公告称，公司控股子公司博创园研发的1类创新药 CKBA软膏白癜风适应症II期临床试验已完成，结果显示积极疗效和良好安全性，达到预期目标，支持 继续开展III期试验。此次CKBA软膏白癜风适应症获得II期临床试验研究初步结果且达到预期目标，进 一步验证了CKBA作为首个靶向T细胞脂肪酸代谢通路的FIC(First-in-Class)创新小分子药物在自身免疫 性疾病领域的巨大开发潜力。公司将加快推进白癜风适应症III期临床试验和玫瑰痤疮适应症II/III期临床 试验，并持续深入开展CKBA在靶点和作用机制方面的基础研究，进一步拓展其在自身免疫性疾病领域 的相关适应症。 ...

Core Viewpoint - The announcement indicates that the clinical trial for the innovative drug CKBA ointment, developed by the subsidiary Bochuangyuan of TianKang (301263), has shown positive efficacy and safety in treating non-segmental vitiligo, supporting the continuation to Phase III trials [1] Group 1: Clinical Trial Results - The Phase II clinical trial data for CKBA ointment has been organized and unblinded, revealing promising results [1] - In the high-dose group (1.5% BID), the proportion of subjects achieving F-VASI50 and F-VASI25 scores was better than that of the placebo group, with 36% (18 out of 50) showing improvement and varying degrees of repigmentation [1] - The main adverse events reported were mild itching and erythema, classified as grade 1-2, with no serious adverse events occurring during the trial [1]